<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9421">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984293</url>
  </required_header>
  <id_info>
    <org_study_id>2016CV05</org_study_id>
    <secondary_id>16/ES/0128</secondary_id>
    <nct_id>NCT02984293</nct_id>
  </id_info>
  <brief_title>Statin Immune Study</brief_title>
  <acronym>ImmunoStat</acronym>
  <official_title>Impact of LILRB5 Genotype on Immune Response to Atorvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins are widely used drugs to treat hypercholesterolaemia. In general, they are very safe
      drugs. However, up to one third of statin users can experience muscle symptoms, which are
      most commonly mild without any conventional laboratory signs of muscle damage. However,
      these muscle symptoms can often lead to poor compliance to the cholesterol-lowering therapy,
      reducing its effectiveness. Recent data has highlighted the potential role of immune system
      in development of statin-induced muscle pain. Variation in the LILRB5 gene has been
      associated with statin intolerance. We aim to investigate the impact of LILRB5 genetic
      variability in tolerability and immune response to atorvastatin in healthy volunteers.

      The study is being undertaken at the Tayside Institute for Cardiovascular Research (TICR) in
      Ninewells Hospital, Dundee. We will recruit participants who have donated a sample to
      GoSHARE study. The participants will be healthy, and recruited according to their genotype
      of LILRB5 (information available from GoSHARE). The volunteers will then enter a randomised
      cross-over study with two treatment periods. During treatment period one, all participants
      will be commenced on atorvastatin or placebo (a dummy drug). Before and at the end of the
      treatment period, blood and urine samples will be taken and a muscle symptoms questionnaire
      will be completed to assess the tolerability and immune response to the study drug exposure.
      After four weeks, the study drug is stopped for a washout period of three weeks before
      cross-over commences. Thereafter, during treatment period two, the alternate study drug will
      be started, and tolerability will be assessed similar to that in period one. The study will
      last approximately 11 weeks. The volunteers have a total of 5 visits to the TICR.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be the change in CK levels at the end of the treatment from baseline in both treatment periods.</measure>
    <time_frame>Measured at baseline (day 0) and day 29 of both treatment periods.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Drug Intolerance</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will receive atorvastatin (80 mg) orally once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants will receive matched placebo orally once daily for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 80 mg once daily for 28 days.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40-60 years

          -  Statin-naïve

          -  Male gender

          -  White European

          -  Healthy

          -  Acceptable laboratory test results

        Exclusion Criteria:

          -  Significant disease

          -  Smoking

          -  Regular drug therapy

          -  Recent involvement (&lt;30 days) in a CTIMP

          -  Inability/unwillingness to comply with the protocol

          -  Carry the rare variant of the CKM polymorphism rs11559024

          -  Unable to consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin NA Palmer, PhD FSB FRSE</last_name>
    <role>Study Chair</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colin NA Palmer, PhD FSB FRSE</last_name>
    <phone>+(44) 01382 383155</phone>
    <email>c.n.a.palmer@dundee.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aleksi Tornio, MD, PhD</last_name>
    <phone>+(44) 01382 383350</phone>
    <email>a.n.n.tornio@dundee.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Dundee</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colin NA Palmer, PhD FSB FRSE</last_name>
      <phone>+(44) 01382 383155</phone>
      <email>c.n.a.palmer@dundee.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Aleksi Tornio, MD, PhD</last_name>
      <phone>+(44) 01382 383350</phone>
      <email>a.n.n.tornio@dundee.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Alex SF Doney, PhD, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.prediction-adr.eu/</url>
    <description>Project website</description>
  </link>
  <reference>
    <citation>Dubé MP, Zetler R, Barhdadi A, Brown AM, Mongrain I, Normand V, Laplante N, Asselin G, Zada YF, Provost S, Bergeron J, Kouz S, Dufour R, Diaz A, de Denus S, Turgeon J, Rhéaume E, Phillips MS, Tardif JC. CKM and LILRB5 are associated with serum levels of creatine kinase. Circ Cardiovasc Genet. 2014 Dec;7(6):880-6. doi: 10.1161/CIRCGENETICS.113.000395. Epub 2014 Sep 11.</citation>
    <PMID>25214527</PMID>
  </reference>
  <reference>
    <citation>Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, Carr DF, Bloch KM, Fahy J, Hanson A, Yue QY, Wadelius M, Maitland-van Der Zee AH, Voora D, Psaty BM, Palmer CN, Pirmohamed M. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014 Oct;96(4):470-6. doi: 10.1038/clpt.2014.121. Epub 2014 Jun 4.</citation>
    <PMID>24897241</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 2, 2016</lastchanged_date>
  <firstreceived_date>December 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atorvastatin</keyword>
  <keyword>LILRB5</keyword>
  <keyword>Statin intolerance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>As per GoSHARE tissue bank protocol, the data derived from the existing samples will be returned to the tissue bank for research use.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
